Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
•
Urology
•
Urologic Oncology
•
Survivorship
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
How long do you generally continue clinical and/or imaging surveillance?
Related Questions
What is the optimal management of malignant mesothelioma of the tunica vaginalis testis (MMTVT) found incidentally after hydrocelectomy?
What additional evaluation or surveillance would you recommend for a patient with a persistently elevated PSA > 50 but repeatedly negative biopsies, MRI, and PSMA PET?
In a patient with very high risk prostate cancer opting for prostatectomy, when, if ever, do you recommend neoadjuvant ADT?
Do you still order mpMRI for staging of prostate cancer in addition to PET-PSMA?
Is it appropriate to offer definitive trimodality therapy, as an equivalent option to neoadjuvant chemotherapy followed by radical cystectomy, in patients with muscle-invasive bladder cancer regardless of fitness or platinum eligibility?
How would you approach adjuvant systemic therapy for an isolated, oligometastatic CNS recurrence of RCC that was treated with SBRT?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
In a patient with metastatic RCC who discontinued nivolumab after a prolonged response to ipilimumab/nivolumab, would you consider re-starting nivolumab at disease progression?
How would you treat a metastatic pure urethral adenocarinoma?
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?